AAAAAA

   
Results: 1-8 |
Results: 8
Therapy of disseminated colorectal cancer: The emerging role of intratumoral molecular biology
Authors: Leichman, L Leichman, CG
Citation: L. Leichman et Cg. Leichman, Therapy of disseminated colorectal cancer: The emerging role of intratumoral molecular biology, EURO J SURG, 167, 2001, pp. 43-48
Predictive and prognostic markers in gastrointestinal cancers
Authors: Leichman, CG
Citation: Cg. Leichman, Predictive and prognostic markers in gastrointestinal cancers, CURR OPIN O, 13(4), 2001, pp. 291-299
Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach
Authors: Garcia, AA Leichman, CG Lenz, HJ Baranda, J Lujan, R Casagrande, Y Leichman, L
Citation: Aa. Garcia et al., Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach, JPN J CLIN, 31(6), 2001, pp. 275-278
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
Authors: Salonga, D Danenberg, KD Johnson, M Metzger, R Groshen, S Tsao-Wei, DD Lenz, HJ Leichman, CG Leichman, L Diasio, RB Danenberg, PV
Citation: D. Salonga et al., Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase, CLIN CANC R, 6(4), 2000, pp. 1322-1327
Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial
Authors: Moinpour, CM Triplett, JS McKnight, B Lovato, LC Upchurch, C Leichman, CG Muggia, FM Tanaka, L James, WA Lennard, M Meyskens, FL
Citation: Cm. Moinpour et al., Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial, PSYCHO-ONC, 9(4), 2000, pp. 340-354
Schedule dependency of 5-fluorouracil
Authors: Leichman, CG
Citation: Cg. Leichman, Schedule dependency of 5-fluorouracil, ONCOLOGY-NY, 13(7), 1999, pp. 26-32
Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors
Authors: Koda, RT Garcia, AA Chatterjee, DJ Li, WY Parimoo, D Jeffers, S Rogers, M Leichman, CG Leichman, L Wu, EY Shetty, BV Webber, S Clendinnin, N Muggia, FM
Citation: Rt. Koda et al., Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors, CANC CHEMOT, 43(6), 1999, pp. 489-496
Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma - A Southwest Oncology Group pilot trial
Authors: Leichman, CG Jacobson, JR Modiano, M Daniels, JR Zalupski, MM Doroshow, JH Fletcher, WS Macdonald, JS
Citation: Cg. Leichman et al., Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma - A Southwest Oncology Group pilot trial, CANCER, 86(5), 1999, pp. 775-781
Risultati: 1-8 |